Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Blood (2023) 141 (14): 1685–1690.

https://doi.org/10.1182/blood.2022017789

Published: 2023

Includes: Supplemental data

Journal Articles

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Pooja Shah, Thorsten Stuehmer, Larissa Haertle, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Martin Kortuem, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2022) 140 (Supplement 1): 7076–7077.

https://doi.org/10.1182/blood-2022-166283

Published: 2022

Journal Articles

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Pooja Shah, Thorsten Stuehmer, Daniela Bruennert, Umair Munawar, Ellen Leich, Sabrina Kraus, Michael Hudecek, Manik Chatterjee, Andreas Schlosser, Ralf C Bargou, Hermann Einsele, Friederike Berberich-Siebelt, Torsten Steinbrunn

Blood (2021) 138 (Supplement 1): 1587.

https://doi.org/10.1182/blood-2021-153741

Published: 2021

Journal Articles

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Blood (2021) 138 (18): 1721–1726.

https://doi.org/10.1182/blood.2020010452

Published: 2021

Includes: Supplemental data

Journal Articles

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Marc S. Raab, MD, Nicola Giesen, MD, Christof Scheid, MD, Britta Besemer, Kaya Miah, Axel Benner, Ivana Metzler, MD, Cyrus Khandanpour, PD, MD, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill, MD, Gunhild Mechtersheimer, Benjamin Goeppert, Albrecht Stenzinger, Hartmut Goldschmidt, MD, Katja Weisel, MD, Manik Chatterjee

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142600

Published: 2020

Journal Articles

Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.

Marcel Seibold, Thorsten Stuehmer, Anja Mottok, Claus J Scholz, Manik Chatterjee, Ellen Leich, Martin Kortüm, Andreas Schlosser, Hermann Einsele, Andreas Rosenwald, Ralf C Bargou, Torsten Steinbrunn

Blood (2018) 132 (Supplement 1): 3217.

https://doi.org/10.1182/blood-2018-99-119804

Published: 2018

Journal Articles

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Marc S Raab, MD PhD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, MD PhD, Hermann Einsele, MD, Monika Engelhardt, MD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Rollig, MD MSC, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Mark Winderlich, PhD, Christian Peschel, MD

Blood (2018) 132 (Supplement 1): 153.

https://doi.org/10.1182/blood-2018-153

Published: 2018

Journal Articles

RAL Mediates Multiple Myeloma Cell Survival Independently of Oncogenic RAS

Marcel Seibold, Thorsten Stuehmer, Nadine Kremer, Anja Mottok, MD PhD, Claus J Scholz, Daniela Bruennert, Manik Chatterjee, Ellen Leich, Andreas Schlosser, Andreas Rosenwald, Hermann Einsele, Ralf C Bargou, Torsten Steinbrunn

Blood (2017) 130 (Supplement 1): 4406.

https://doi.org/10.1182/blood.V130.Suppl_1.4406.4406

Published: 2017

Journal Articles

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Marc S. Raab, MD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, Hermann Einsele, MD, Monika Engelhardt, MD PhD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Jan Endell, PhD, Rainer Boxhammer, PhD, Christian Peschel, MD

Blood (2016) 128 (22): 1152.

https://doi.org/10.1182/blood.V128.22.1152.1152

Published: 2016

Journal Articles

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Santiago Barrio, PhD, Thorsten Stühmer, PhD, Eva Teufel, Clara Barrio-Garcia, Manik Chatterjee, MD, Martin Schreder, MD, Mithun Das Gupta, MD, Andreas Rosenwald, MD, Raoul Tibes, MD PhD, Esteban Braggio, PhD, A. Keith Stewart, MD, Ralf C Bargou, MD, Hermann Einsele, MD, K Martin Kortüm, MD

Blood (2016) 128 (22): 3282.

https://doi.org/10.1182/blood.V128.22.3282.3282

Published: 2016

Journal Articles

Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study

Monica Galli, MD, Hila Magen, MD, Hermann Einsele, Manik Chatterjee, MD, Mariella Grasso, MD, Giorgina Specchia, Paola Barbieri, MD, David Paoletti, MS, Silvia Pace, MS, Ralph D Sanderson, PhD, Alessandro Rambaldi, MD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 3246.

https://doi.org/10.1182/blood.V126.23.3246.3246

Published: 2015

Journal Articles

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

Marc S Raab, MD PhD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor W Blau, MD PhD, Hermann Einsele, MD, Monika Engelhardt, MD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Röllig, MD, Katja C. Weisel, Pia Klöpfer, MD, Dominika Weinelt, MD, Stefan Härtle, PhD, Christian Peschel, MD

Blood (2015) 126 (23): 3035.

https://doi.org/10.1182/blood.V126.23.3035.3035

Published: 2015

Journal Articles

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

Torsten Steinbrunn, Thorsten Stühmer, Stefan Gattenlöhner, Andreas Rosenwald, Anja Mottok, Christian Unzicker, Hermann Einsele, Manik Chatterjee, Ralf C. Bargou

Blood (2011) 117 (6): 1998–2004.

https://doi.org/10.1182/blood-2010-05-284422

Published: 2011

Includes: Supplemental data

Journal Articles

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

Unn-Merete Fagerli, MD, PhD, Thorsten Stühmer, PhD, Toril Holien, Randi Utne Holt, PhD, Ove Bruland, PhD, Manik Chatterjee, MD, John Shaughnessy, Jr, PhD, Stephan Mathas, MD, Anders Sundan, MD, Ralf C Bargou, MD, Bernd Dörken, MD, Magne Borset, MD, PhD, Martin Janz, MD

Blood (2010) 116 (21): 1915.

https://doi.org/10.1182/blood.V116.21.1915.1915

Published: 2010

Journal Articles

Analysis of PKB/Akt-Signaling and Oncogenic Ras in Multiple Myeloma.

Torsten Steinbrunn, Thorsten Stühmer, Manik Chatterjee, Stefan Gattenlöhner, Ralf C Bargou

Blood (2009) 114 (22): 831.

https://doi.org/10.1182/blood.V114.22.831.831

Published: 2009

Journal Articles

Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.

Tanja Heimberger, Mindaugas Andrulis, Stephanie Fischbach, Thorsten Stühmer, Hermann Einsele, Ralf C. Bargou, Manik Chatterjee

Blood (2009) 114 (22): 2829.

https://doi.org/10.1182/blood.V114.22.2829.2829

Published: 2009

Journal Articles

Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease

Claudia Stuehler, Stephan Mielke, Manik Chatterjee, Johannes Duell, Sarah Lurati, Florian Rueckert, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2009) 114 (13): 2829–2836.

https://doi.org/10.1182/blood-2009-06-224600

Published: 2009

Journal Articles

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

Angela Zöllinger, Thorsten Stühmer, Manik Chatterjee, Stefan Gattenlöhner, Eugenia Haralambieva, Hans-Konrad Müller-Hermelink, Mindaugas Andrulis, Axel Greiner, Carmen Wesemeier, Jörg C. Rath, Hermann Einsele, Ralf C. Bargou

Blood (2008) 112 (8): 3403–3411.

https://doi.org/10.1182/blood-2007-11-119362

Published: 2008

Includes: Supplemental data

Journal Articles

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

Manik Chatterjee, Christoph Rancso, Thorsten Stühmer, Niels Eckstein, Mindaugas Andrulis, Christian Gerecke, Heike Lorentz, Hans-Dieter Royer, Ralf C. Bargou

Blood (2008) 111 (7): 3714–3722.

https://doi.org/10.1182/blood-2007-05-089151

Published: 2008

Includes: Supplemental data

Journal Articles

AKT Dependent and AKT Independent Multiple Myeloma: Heterogeneity in Tumor Cell Signaling.

Angela Zöllinger, Thorsten Stühmer, Manik Chatterjee, Ralf C. Bargou

Blood (2007) 110 (11): 1511.

https://doi.org/10.1182/blood.V110.11.1511.1511

Published: 2007

NARROW

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAF V600E -mutated multiple myeloma

Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

CD200 Expression on Multiple Myeloma Cells Induces Attenuation of T Cell-Mediated Cytotoxicity Via DOK2

Cereblon enhancer methylation and IMiD resistance in multiple myeloma

Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial

Activated Ral and Mutated RAS Are Independent Drivers of Multiple Myeloma Cell Survival.

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

RAL Mediates Multiple Myeloma Cell Survival Independently of Oncogenic RAS

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Parallel Evolution of Multiple PSMB5 mutations in a Myeloma Patient Treated with Bortezomib

Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study

Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

Serum/Glucocorticoid-Regulated Kinase 1 (SGK1) Is a Prominent Target Gene of the Transcriptional Response to Cytokines In Multiple Myeloma and Supports the Growth of Myeloma Cells

Analysis of PKB/Akt-Signaling and Oncogenic Ras in Multiple Myeloma.

Inhibition of the Heat Shock Transcription Factor 1 as a Potential New Therapeutic Strategy to Target Multiple Oncogenic Heat Shock Proteins in Multiple Myeloma.

Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma

AKT Dependent and AKT Independent Multiple Myeloma: Heterogeneity in Tumor Cell Signaling.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only